Treatments

*March 2025* Fort Lee, NJ, March 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced a  new publication from…

*March 2025* Cell-based immunotherapies such as chimeric antigen receptor T cells (CAR-T) have transformed cancer care in recent years, dramatically improving the treatment of blood cancers in particular. But traditional autologous CAR-T therapy has some drawbacks that may limit how many patients it can help. Harvesting, engineering and readministering a…

*March 2025* Hear from experts Dr. Jona Hattangadi-Gluth and Dr. Jonathan Yang about radiation therapy for leptomeningeal cancer. Learn the difference between proton and photon therapy, how treatment plans are developed, and the latest in clinical trials. Watch here.

*March 2025* The FDA has granted orphan drug designation to the investigational radiotherapeutic rhenium (186Re) obisbemeda as a potential therapeutic option for leptomeningeal metastases in patients with lung cancer.1 Rhenium (186Re) obisbemeda is formulated to deliver highly targeted, high-dose radiation directly to central nervous system (CNS) tumors with the goal…

*March 2025* MARIPOSA2 Study: What happens if you are on osimertinib and it stops working? Can you still get amivantamab? Dr. Eric Singhi explains here. MARIPOSA Study: Amivantamab + lazertinib vs osimertinib OS benefit in first-line. Dr. Eric Singhi explains here. Jill Feldman: Presenting COCOON and MARIPOSA together tells a…

*March 2025* What is the next step for patients with EGFR-mutated non-small cell lung cancer (NSCLC) whose disease has progressed on first-line osimertinib (Tagrisso), but who have no identifiable biomarkers to guide second-line therapy? Early results from the phase 2 ORCHARD platform study suggest that the next step could be adding the…

*February 2025* Key Takeaways Zongertinib selectively inhibits HER2, sparing EGFR, to limit toxicities in NSCLC treatment. Phase 1 Beamion LUNG-1 trial showed a 71% ORR, with favorable safety and tolerability. Priority review highlights the urgent need for new treatments in HER2-mutant NSCLC. Zongertinib is under further evaluation in a phase…

*February 2025* Two decades ago, the discovery of the EGFR mutation transformed lung cancer treatment. The finding led to dramatically improved survival rates and ushered in the era of precision medicine and molecular profiling for lung cancer. In a special episode of the new Cancer Letter Podcast, Suresh S. Ramalingam,…

*February 2025* Highlights Lazertinib-amivantamab combination shows potent activity in uncommon EGFR-mutant NSCLC The combination can overcome resistance of uncommon EGFR mutations to EGFR-TKIs Lazertinib enhances the on-target expression of amivantamab High EGFR/MET expression associates with response to combination therapy Summary Uncommon epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC)…